Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caribou Biosciences Inc (NQ: CRBU )

2.200 +0.180 (+8.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,105,101
Open 2.040
Bid (Size) 2.130 (20)
Ask (Size) 2.200 (4)
Prev. Close 2.020
Today's Range 2.000 - 2.200
52wk Range 1.500 - 8.330
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-60.50%
-60.50%
1 Month
+13.99%
+13.99%
3 Month
+4.27%
+4.27%
6 Month
-22.81%
-22.81%
1 Year
-63.09%
-63.09%

More News

Read More
Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Expert Ratings For Caribou Biosciences
Via Benzinga
Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Evaluating Caribou Biosciences: Insights From 4 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences
Via Benzinga
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Expert Ratings For Caribou Biosciences
Via Benzinga
Attention Biotech Investors - Stocks To Watch
Via Benzinga
3 Underappreciated Stocks That Could 10x in 10 Years
Via InvestorPlace
CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Caribou Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.